Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older

Oren Auster; Uriah Finkel; Noa Dagan; Noam Barda; Alon Laufer; Ran D Balicer; Shay Ben-Shachar

doi:10.1001/jamanetworkopen.2022.7657

Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older

Oren Auster, Uriah Finkel, Noa Dagan, Noam Barda, Alon Laufer, Ran D Balicer, Shay Ben-Shachar

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Introduction
On July 29, 2021, concerns of waning immunity after Pfizer-BioNTech BNT162B2 mRNA vaccination led the Israeli Ministry of Health to start a campaign to administer booster (third) doses to individuals who received their second dose at least 5 months prior.1,2 The booster was initially approved for individuals 60 years or older. This survey study assessed the occurrence of adverse effects (AEs) in adults 60 years or older who received a booster dose.

Original language	English
Pages (from-to)	e227657
Journal	JAMA network open
Volume	5
Issue number	4
DOIs	https://doi.org/10.1001/jamanetworkopen.2022.7657
State	Published - 1 Apr 2022

ASJC Scopus subject areas

Medicine (all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1001/jamanetworkopen.2022.7657

Cite this

@article{c2d442e9cf3040f98ed5c5b387224fc4,

title = "Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older",

abstract = "IntroductionOn July 29, 2021, concerns of waning immunity after Pfizer-BioNTech BNT162B2 mRNA vaccination led the Israeli Ministry of Health to start a campaign to administer booster (third) doses to individuals who received their second dose at least 5 months prior.1,2 The booster was initially approved for individuals 60 years or older. This survey study assessed the occurrence of adverse effects (AEs) in adults 60 years or older who received a booster dose.",

author = "Oren Auster and Uriah Finkel and Noa Dagan and Noam Barda and Alon Laufer and Balicer, {Ran D} and Shay Ben-Shachar",

year = "2022",

month = apr,

day = "1",

doi = "10.1001/jamanetworkopen.2022.7657",

language = "English",

volume = "5",

pages = "e227657",

journal = "JAMA network open",

issn = "2574-3805",

publisher = "American Medical Association",

number = "4",

}

TY - JOUR

T1 - Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older

AU - Auster, Oren

AU - Finkel, Uriah

AU - Dagan, Noa

AU - Barda, Noam

AU - Laufer, Alon

AU - Balicer, Ran D

AU - Ben-Shachar, Shay

PY - 2022/4/1

Y1 - 2022/4/1

N2 - IntroductionOn July 29, 2021, concerns of waning immunity after Pfizer-BioNTech BNT162B2 mRNA vaccination led the Israeli Ministry of Health to start a campaign to administer booster (third) doses to individuals who received their second dose at least 5 months prior.1,2 The booster was initially approved for individuals 60 years or older. This survey study assessed the occurrence of adverse effects (AEs) in adults 60 years or older who received a booster dose.

AB - IntroductionOn July 29, 2021, concerns of waning immunity after Pfizer-BioNTech BNT162B2 mRNA vaccination led the Israeli Ministry of Health to start a campaign to administer booster (third) doses to individuals who received their second dose at least 5 months prior.1,2 The booster was initially approved for individuals 60 years or older. This survey study assessed the occurrence of adverse effects (AEs) in adults 60 years or older who received a booster dose.

UR - http://www.scopus.com/inward/record.url?scp=85128796885&partnerID=8YFLogxK

U2 - 10.1001/jamanetworkopen.2022.7657

DO - 10.1001/jamanetworkopen.2022.7657

M3 - Article

C2 - 35435973

SN - 2574-3805

VL - 5

SP - e227657

JO - JAMA network open

JF - JAMA network open

IS - 4

ER -

Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this